key: cord-0015666-lwe090wh
authors: Frost, Joe N.; Tan, Tiong Kit; Abbas, Munawar; Wideman, Sarah K.; Bonadonna, Michael; Stoffel, Nicole U.; Wray, Katherine; Kronsteiner, Barbara; Smits, Gaby; Campagna, Dean R.; Duarte, Tiago L.; Lopes, José M.; Shah, Akshay; Armitage, Andrew E.; Arezes, João; Lim, Pei Jin; Preston, Alexandra E.; Ahern, David; Teh, Megan; Naylor, Caitlin; Salio, Mariolina; Gileadi, Uzi; Andrews, Simon C.; Dunachie, Susanna J.; Zimmermann, Michael B.; van der Klis, Fiona R.M.; Cerundolo, Vincenzo; Bannard, Oliver; Draper, Simon J.; Townsend, Alain R.M.; Galy, Bruno; Fleming, Mark D.; Lewis, Marie C.; Drakesmith, Hal
title: Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection
date: 2021-02-12
journal: Med (N Y)
DOI: 10.1016/j.medj.2020.10.004
sha: 74f87a519c2568d885fa4e41787f0c10fbfd76f9
doc_id: 15666
cord_uid: lwe090wh

BACKGROUND: How specific nutrients influence adaptive immunity is of broad interest. Iron deficiency is the most common micronutrient deficiency worldwide and imparts a significant burden of global disease; however, its effects on immunity remain unclear. METHODS: We used a hepcidin mimetic and several genetic models to examine the effect of low iron availability on T cells in vitro and on immune responses to vaccines and viral infection in mice. We examined humoral immunity in human patients with raised hepcidin and low serum iron caused by mutant TMPRSS6. We tested the effect of iron supplementation on vaccination-induced humoral immunity in piglets, a natural model of iron deficiency. FINDINGS: We show that low serum iron (hypoferremia), caused by increased hepcidin, severely impairs effector and memory responses to immunizations. The intensified metabolism of activated lymphocytes requires the support of enhanced iron acquisition, which is facilitated by IRP1/2 and TFRC. Accordingly, providing extra iron improved the response to vaccination in hypoferremic mice and piglets, while conversely, hypoferremic humans with chronically increased hepcidin have reduced concentrations of antibodies specific for certain pathogens. Imposing hypoferremia blunted the T cell, B cell, and neutralizing antibody responses to influenza virus infection in mice, allowing the virus to persist and exacerbating lung inflammation and morbidity. CONCLUSIONS: Hypoferremia, a well-conserved physiological innate response to infection, can counteract the development of adaptive immunity. This nutrient trade-off is relevant for understanding and improving immune responses to infections and vaccines in the globally common contexts of iron deficiency and inflammatory disorders. FUNDING: Medical Research Council, UK

Adaptive immunity is essential for protection from infectious disease and for the preservation of health. After activation, antigen-specific lymphocytes proliferate rapidly, differentiate, and acquire effector functions, necessitating accelerated metabolism and macromolecular synthesis. 1 Iron is necessary for many fundamental

Iron deficiency is very common in humans and animals. Frost et al demonstrate that low concentrations of iron in serum, caused by the hormone hepcidin, inhibit the body's response to vaccines and infections; conversely, increasing iron can boost immunity. cellular processes, including DNA synthesis, the tricarboxylic acid cycle, and oxidative phosphorylation, 2 and a rare mutation in transferrin receptor that disrupts the ability of cells to acquire iron causes immunodeficiency. 3 The high global prevalence of iron deficiency and anemia results from a combination of nutritional iron deficiency, blood loss, and inflammation-induced hepcidin. 4 The master iron regulatory hormone hepcidin suppresses dietary iron absorption and macrophage iron recycling by inhibiting the iron-exporter protein, ferroportin, which releases iron into serum. 5, 6 Hepcidin expression is regulated both by iron, as part of homeostatic mechanisms, 5, 7 and inflammation, as part of the innate immune responses that attempt to deny iron to invading pathogens. 8 Hepcidin rapidly decreases serum iron concentrations, and persistent high hepcidin and hypoferremia can lead to anemia. 9 We found very low concentrations of serum iron and high hepcidin levels (driven by inflammation) in Gambian infants. 10, 11 There have been many studies linking iron deficiency and impaired immunity, but results have been inconsistent, and the methods used to define iron deficiency and to analyze immune responses have varied considerably, leading to uncertainty. 12, 13 More recent reports have suggested that iron can exacerbate autoimmune T cell activity, 14 and severe nutritional iron deficiency may impair B cell-proliferative responses. 15 However, whether hepcidin, as the iron-regulatory hormone, influences adaptive immunity to vaccination and infection is unknown. In this study, we show how physiological variation in serum iron concentrations, controlled by hepcidin or iron supplementation, profoundly influences lymphocyte biology and immune responses.

To begin testing how changes in serum iron levels affect the adaptive immune response, mice were placed on a low iron diet (2 ppm Fe) to model low iron supply. Three days after immunization, the mice were injected daily with minihepcidin (a mimetic of hepcidin with the same mechanism of action 16 ), which transiently suppresses serum iron concentrations to~5 mmol/L ( Figures 1A and S1A ). Mice in the low iron treatment group had low serum iron and decreased endogenous liver hepcidin mRNA expression ( Figure 1A , indicating low iron stores), and exhibited a profoundly suppressed antigen-specific CD8 T cell response to immunization with recombinant adenovirus encoding ovalbumin (AdHu5-ovalbumin [OVA] ) and to OVA protein in adjuvant ( Figures 1B and 1C ). In addition, the T follicular helper cell, germinal center (GC) B cell, and plasma cell responses were strikingly reduced, and anti-OVA IgG titers were suppressed ( Figure 1D ). We dissected the key aspects of altered iron homeostasis that influenced the adaptive immune response. Mice on a low iron diet for 4 weeks had substantially decreased liver iron and liver hepcidin mRNA, indicating low iron stores, but serum iron remained unchanged, and the antigen-specific CD8 + T cell and GC B cell responses to immunization were unaltered (Figures S1B and S1C). The lack of effect of 4 weeks of a low iron diet to alter serum iron, but to deplete liver iron, was reproducible in the absence of immunization (Figure S1D) , and a low iron diet did not alter the growth rate of mice ( Figure S1E ). Furthermore 4 weeks of a low iron diet only resulted in mild microcytic hypochromic anemia ( Figure S1F ).

In mice on a normal iron diet (188 ppm Fe), a single injection of minihepcidin 3 h before immunization with OVA in adjuvant, to cause low serum iron for~24 h concurrent with dendritic cell (DC)-T cell interactions, did not alter the magnitude of subsequent OT-I (OVA-specific CD8 + T cell) responses ( Figure S1G ). However, 2 injections of minihepcidin on days 3 and 4 after immunization were sufficient to suppress the expansion of OT-I cells, and the fewer responding cells had increased transferrin receptor (TFRC) expression, indicating relative cellular iron deficiency, and liver hepcidin mRNA was decreased, which is consistent with hypoferremia ( Figure 1E ). The injection of ferric ammonium citrate rescued the minihepcidininduced suppression of OT-I expansion, decreased TFRC expression on responding T cells, and increased liver hepcidin mRNA ( Figure 1E ). Neither hepcidin peptide nor minihepcidin directly altered T cell proliferation or TFRC expression in vitro ( Figures S2A-S2C) , suggesting that the in vivo effect of minihepcidin is mediated via iron redistribution during the expansion phase of the immune response. Hepcidin causes hypoferremia in part by sequestering iron in splenic macrophages. However, injecting mice with iron-dextran, which induces iron accumulation in splenic macrophages without decreasing serum iron, did not (unlike minihepcidin) inhibit the OT-I response to immunization ( Figures S2D-S2G ). Therefore, decreased serum iron, caused by minihepcidin, is necessary and sufficient for impairing the response of activated and proliferating antigen-specific lymphocytes to immunization. (D) Number of T follicular helper cells (PD-1 + CXCR5 + CD44 + CD4 T cells), germinal center (GC) B cells (IgD À CD95 + B220 + B cells), plasma cells (CD138 + IgD À cells), and anti-OVA IgG titer (a.u., arbitrary unit) 7 days after immunization with OVA in adjuvant. Means G SDs. Student's 2-tailed t test, unpaired. (E) Experimental design to determine whether parenteral iron supplementation can reverse the effect of minihepcidin injection; FAC = ferric ammonium citrate. Left: the frequency of antigen-specific splenic OT-I CD8 T cells; center: normalized relative mean fluorescence intensity (MFI) of surface CD71 expression by OT-I CD8 T cells 5 days after OVA and adjuvant immunization were detected with flow cytometry; right: liver hepcidin mRNA. Means G SDs. One-way ANOVA with correction for multiple comparisons.

Exploring this concept in more depth, we found that minihepcidin injections decreased the endogenous CD8 T cell OVA-specific response to AdHu5-OVA in the spleen and peripheral blood, the splenic OT-I response to Modified Vaccinia Ankara encoding OVA (MVA-OVA), the splenic OT-I response to OVA in adjuvant, and the endogenous CD8 T cell splenic vaccinia-specific (B8R peptide) response to MVA-OVA, all in mice on a standard iron diet (Figures 2A and 2B ). Beyond the effects on proliferation, OT-I CD8 cells from minihepcidin-treated mice secreted less of the effector cytokines interferon g (IFNg) and tumor necrosis factor-a (TNF-a), and fewer of these cells produced interleukin-2 (IL-2), on ex vivo restimulation ( Figure 2C ). Minihepcidin also suppressed the endogenous cytokine-producing effector CD4 T cell response to MVA-OVA and the CD4 OT-II T follicular helper cell response to OVA in adjuvant; furthermore fewer splenic OT-II CD4 effector cells secreted IL-2 or TNF-a on restimulation with peptide ex vivo, and splenic GC B cell responses were suppressed ( Figures 2D and 2E ). In summary, hypoferremia inhibits several elements of immune responses across multiple vaccination platforms and different antigens.

To investigate the cell-intrinsic nature of iron-dependent responses, we tested how the Y20H mutation in TFRC, which impairs cellular iron uptake and causes immunodeficiency in humans, 3 influences lymphocyte responses to immunization. Competitive bone marrow transplant experiments were performed in which bone marrow from wild-type (WT) mice and Tfrc Y20H/Y20H mice were mixed and transferred into lethally irradiated WT recipient mice, and both lymphopoiesis and response to immunization were analyzed ( Figure 3A ). The Tfrc Y20H/Y20H allele did not influence the reconstitution of T cells or B cells into the circulation ( Figure 3B ), but after immunization with MVA-OVA, responding antigen-specific CD8 T cells, T follicular helper cells, and GC B cells carrying the Tfrc Y20H/Y20H allele were underrepresented compared to their WT counterparts, indicating that the Tfrc Y20H/Y20H mutation bestows cell-intrinsic defects to proliferative lymphocyte responses specifically after immunization ( Figure 3C ).

To understand the basis of T cell sensitivity to iron deprivation, we assessed the expression of key iron-handling proteins 5 in the first 24 h after the activation of CD8 T cells in standard cell culture media from published datasets. 17 TFRC was highly upregulated, ferrous ion importers DMT1 (Slc11a2) and ZIP14 (Slc39a14) and intracellular iron sensors 18 IRP1 and IRP2 (iron-responsive element-binding proteins 1 and 2) were also increased, while levels of the iron-storage protein ferritin (FTL and FTH) were not significantly altered; the iron export protein ferroportin (Slc40a1) was not detected, but ferroportin mRNA expression was strongly decreased after activation ( Figures S3A and S3B) . These changes indicate a drive to sense, acquire, and retain iron after activation. IRP1 and IRP2 control cellular iron homeostasis. 18 To test the functional importance of these regulators in CD8 + T cells, we used floxed Irp1 and Irp2 alleles that are excised via a tamoxifen-activated Cre-ERT2 recombinase ( Figure S3C ). Stimulated CD8 + T cells induced to delete Irp1 and Irp2 did not upregulate TFRC to the same extent as control cells and proliferated relatively poorly; however, proliferation was substantially improved by the addition of inorganic FeSO 4 , which is taken up independently of TFRC ( Figures 4A, 4B , and S3D). Thus, Irp1/2 control of TFRCmediated T cell iron acquisition is required for proliferation after activation. (B) Antigen-specific T cell populations quantified by flow cytometry 7 days after immunization. Left to right: number of splenic endogenous OVA-specific CD8 T cells after AdHu5-OVA immunization, frequency of endogenous OVA-specific CD8 T cells as a percentage of total CD8s in peripheral blood after AdHu5-OVA immunization, number of splenic OT-I OVA-specific CD8 T cells after MVA-OVA immunization, number of splenic OT-I OVA-specific CD8 T cells after OVA and adjuvant immunization, and frequency of endogenous vaccinia (B8R epitope)-specific CD8 T cells as a percentage of total CD8s, resolved by IFNg production after ex vivo peptide restimulation, induced by MVA-OVA immunization. Means G SDs. t test. Student's 2-tailed t test, unpaired. (C) Left to right: relative MFI of IFNg and TNF-a for OT-I effector cells producing the respective cytokine, MFI normalized to average of vehicle group; percentage of OT-I effector cells that secrete IL-2. Cytokine-producing cells resolved by intracellular cytokine staining after ex vivo restimulation of splenocytes from mice with SIINFEKL peptide 7 days after MVA-OVA immunization. Means G SDs. t test. Student's 2-tailed t test, unpaired. (D) Frequency of endogenous vaccinia-specific IFNg, TNF-a, or IL-2 producing CD40L + CD4 Th1 effector T cells as a percentage of total CD4s, resolved by intracellular cytokine staining after ex vivo restimulation of splenocytes with MVA-OVA-pulsed dendritic cells. Means G SDs. t test. Student's 2-tailed t test, unpaired. (E) Number of splenic OT-II T follicular helper cells induced by OVA and adjuvant immunization. Frequency of splenic TNF-a + and IL-2 + OT-II effector cells induced by OVA and adjuvant immunization as a percentage of total OT-II CD4 T cells after ex vivo restimulation with peptide. Frequency of splenic GC B cells as a percentage of B cells after OVA and adjuvant immunization. All 7 days post-immunization. Means G SDs. t test. Student's 2-tailed t test, unpaired.

168 Med 2, 164-179, February 12, 2021 To further explore the effect of low iron availability on aspects of T cell physiology, we activated WT CD8 T cells in vitro across a range of transferrin-iron concentrations. Low iron did not alter early CD69 upregulation but resulted in fewer cells with higher than 2N DNA content within 24 h and decreased proliferation over 3 days (Figure S3E ). Iron deficiency reduced total cellular ATP content 24 h after activation and decreased ATP production due to lower mitochondrial ATP generation, while A B C Figure 3 . Iron Uptake via the Transferrin Receptor Is Cell-Intrinsically Essential for Immune Responses (A) Experimental design for establishing mixed bone marrow chimeras to investigate cell-intrinsic effect of Tfrc Y20H/Y20H allele on immune response in vivo. Data from Tfrc Y20H/Y20H ; WT chimeras are displayed in red, whereas data from WT;WT chimeras are in blue. (B) Ratio of the frequencies of CD45.2:CD45.1 cells within peripheral blood CD8 T cells, CD4 T cells, and B cells at 65 days after establishment of chimeras, determined by flow cytometry. Means G SDs. Student's 2-tailed t test, unpaired. (C) Comparison of the ratio of the frequencies of CD45.2:CD45.1 cells within naive and effector lymphocyte populations within each chimeric mouse, 72 days after establishment of chimeras and 1 week after MVA-OVA immunization. The data are displayed for naive (CD44 À ) and effector tetramer + splenic CD8 T cells, dLN naive (CD44 À ) CD4 T cells and T follicular helper cells (PD-1 + CXCR5 + CD44 + CD4 T cells), and dLN naive follicular (IgD + , CD95 À ) and GC B cells (IgD À CD95 + GL7 + B cells). Student's 2-tailed t test, paired.

Med 2, 164-179, February 12, 2021 169 glycolytic ATP production was unaltered, and after 72 h, iron-deficient T cells had relatively depolarized mitochondria ( Figure 4C ). Notably, DNA synthesis and mitochondrial ATP synthesis are iron-dependent processes, while in contrast none of the 10 enzymes that mediate glycolysis appear to require iron.

Mammalian target of rapamycin complex 1 (mTORC1) senses diverse environmental signals and is an important regulator of T cell differentiation 17,19 ; while iron-dependent regulation of mTORC1 can regulate the erythroid response to iron deficiency, 20 the presence of this signaling axis in other primary cell types is unknown. We found that low iron also reduced CD8 + T cell mTORC1 activity (as measured by intracellular phosphorylated S6 ribosomal protein) and expression of the amino acid transporter CD98, and decreased cell size ( Figure S3F ). Furthermore, granzyme B and the IL-2 receptor (CD25) levels were reduced, indicating an impaired effector phenotype ( Figure S3G ). In complementary experiments, we increased iron availability to activated CD8 T cells from Tfrc Y20H/Y20H mice by providing iron in forms that bypass the defective Y20H TFRC protein ( Figure S4A ). Rapid CD69 upregulation was unaffected, but FeSO 4 improved Tfrc Y20H/Y20H CD8 T cell ATP content, mitochondrial health, increased cell size and the percentage of phospho-S6 + cells, and rescued proliferation ( Figures S4B-S4D activation, CD8 T cells transform their ability to acquire iron, and iron is required for T cell mitochondrial and effector functions, optimal metabolic activity, and cell-cycle progression.

The in vitro requirements of T cells for iron and the strong effects of hypoferremia on primary immune responses led us to test whether low iron availability had longerterm effects on the formation of immunological memory. We transferred OT-I cells into recipient mice, injected OVA protein in adjuvant, then treated mice with minihepcidin daily for 4 days; 28 days later, at which point serum iron was normalized, there were marginally decreased total splenic OT-I memory cells and a marked significant reduction in the frequency of memory cells with a central memory-like phenotype (CD62L + ; or CD27 + , CD43 À ; or CX3CR1 À ) 21,22 from mice that had received minihepcidin during priming ( Figure S5A ). Following in vitro restimulation, fewer splenic memory cells capable of synthesizing IL-2, IFNg, and TNF-a (individually or combined) were detected in mice that had experienced low serum iron during the primary immune response; responding cells also produced less of each cytokine ( Figures S5B-S5E) . Finally, to test recall responses in a separate experiment, mice that had been injected with OVA in adjuvant with or without minihepcidin on days 3-6 post-immunization were re-challenged with OVA subcutaneously on day 35 after immunization and the secondary response analyzed on day 40. Hypoferremia during priming reduced the OVA-specific CD8 T cell recall response and the percentage of IFNg-producing CD8 + T cells ( Figure 5A ). Hence, transient hypoferremia during primary responses impairs the quality and quantity of subsequent T cell memory and recall capacity in mice.

To understand whether similar principles of iron-limiting immune responses apply in species with different metabolic needs, we took advantage of the natural piglet physiology, in which the low iron reserves at birth due to large litter size, rapid post-natal growth, and iron-poor sow's milk necessitates additional provision of iron to prevent the swift onset of anemia. 23 In piglets reared only on sow's milk replacer without added iron, serum iron was relatively low and hemoglobin levels dropped steadily in the 4 weeks after birth; the red blood cell number was also decreased while platelets were increased, indicating iron-deficiency anemia (IDA) ( Figures 6A, S6A , and S6B). At 2 weeks of age, piglets were vaccinated against Mycoplasma hyopneumoniae (a standard immunization against an important piglet pathogen 24 ), at which time there was no significant difference in antibody titer (Figure S6C ). Two weeks later, the vaccine-specific antibody response was relatively increased in the piglets that had received iron ( Figures 6B and S6C) . Therefore, against a background of IDA, iron supplementation not only maintains hemoglobin but can also improve responses to vaccination.

A rare form of iron-refractory IDA (IRIDA) in humans is caused by increased hepcidin in patients with mutations in TMPRSS6, a protease that normally represses hepcidin. 25 The quality of adaptive immunity in IRIDA patients has not been explored before. We investigated antibodies specific for various pathogens that are targeted by vaccines in a group of 12 IRIDA patients who had increased hepcidin levels, hypoferremia (~5 mmol/L serum Fe) and hematological parameters indicative of IDA ( Figure S6D ) compared to controls of similar age collected at the same clinic ( Figure 6C ). None of the IRIDA patients (and controls) had raised Creactive protein (all IRIDA patients <0.5 mg/L), indicating a lack of systemic inflammation ( Figure S6D ). Compared to the control group, the IRIDA group had lower serum immunoglobulin G (IgG) concentrations against rubella, Hib and anti-Streptococcus pneumoniae serotype 1 (PS1), a leading cause of invasive pneumococcal disease globally 26 ( Figure 6D ). For anti-PS1, none of the IRIDA patients achieved an antibody concentration above the World Health Organization (WHO) protective threshold of 0.35 mg/mL ( Figure 6D ), and overall, IRIDA patients were less likely to achieve protective concentrations to S. pneumoniae serotypes (Figure S6E ). Controlling for age and gender, we found genotype effects on anti-PS1 (p = 0.005), anti-PS18C (p = 0.048), and anti-Hib (p = 0.066) serum IgG (all lower in the IRIDA group). These data show that a condition of persistently high hepcidin associates with lower antibody levels against some important pathogens in humans.

Innate immune responses to infection increase hepcidin, contributing to hypoferremia of infection. 8 We investigated how minihepcidin treatment, to enforce prolonged hypoferremia, influenced the immune response to a respiratory viral infection (influenza A virus) in mice ( Figure 7A ). We observed fewer virus-specific CD8 T cells in the spleen and lungs; fewer granzyme B-expressing splenic CD8 T cells; and fewer T-follicular helper cells, antigen-experienced CD44 + CD4 cells, and GC B cells in the mediastinal lymph nodes on day 8 post-infection (Figures 7B and 7C); however, lung mRNA expression of pro-inflammatory cytokines IL-6 and TNF-a was higher ( Figure S7A ). Cellular immune responses in the spleen were also reduced on day 10 post-infection ( Figure S7B ), circulating influenza neutralizing antibodies were undetectable ( Figure 7D ), and lung viral load (measured as influenza nucleoprotein RNA) was significantly higher ( Figure 7E ). Histologically, focal airway inflammation was present in all of the infected mice, but despite suppressed lymphocyte responses, perivascular/peribronchiolar inflammation was more severe in the lungs of minihepcidin-treated infected mice, with marked extension into the alveolar parenchyma ( Figures 7F and 7G) . The increased inflammatory cell infiltrates in minihepcidin-treated mice comprised both mononuclear cells and neutrophils, with larger areas of the lung exhibiting disrupted alveolar structures (Figures 7F, 7G S7C, and S7D); however, no change in lung non-heme iron content was observed ( Figure S7E ). In addition to this increased tissue damage, minihepcidin-treated mice failed to recover infection-induced weight loss ( Figure S7F ). Therefore, mice with persistent hypoferremia had a suppressed adaptive immune response, were less able to clear the virus, and experienced more severe pulmonary disease and sustained morbidity.

Hepcidin-induced hypoferremia is a well-conserved component of the innate immune response in vertebrates. 8 We demonstrate that hypoferremia may impair multiple aspects of adaptive immunity if it occurs during the period of lymphocyte expansion, with the potential for subsequent long-term inhibition of T cell memory even after hypoferremia has resolved. We show that appropriate regulation of cellular iron uptake controlled by IRP1/2 is essential for T cell effector functions; and TFRC-mediated iron acquisition is cell-intrinsically required for B and T cell responses in vivo. The remarkable upsurge in the expression of TFRC by activated T cells, increasing by~1 million copies of protein per cell within 24 h, along with escalations in transmembrane iron importers, indicates a significant intensification of efforts to acquire iron from extracellular sources. Although we showed that oxidative metabolism and DNA synthesis studies are two iron-dependent processes inhibited in T cells by low iron availability, many other cellular pathways important in T cell biology, including epigenetic reprogramming and hypoxia sensing, also require iron and should be investigated. Furthermore, reduced CD25 expression and failure to sense IL-2 could contribute to the poorer quality of effector/memory CD8 T cells observed in iron deficiency. 27 Because the accelerated metabolic activity of activated lymphocytes is particularly sensitive to iron availability, physiological variations in iron concentrations strongly influence immune responses. Therefore, iron may be considered a nutrient relevant to concepts of immunometabolism. 28 Hepcidin, Hypoferremia, and Viral Infections Hepcidin-controlled iron redistribution protects against some bacterial infections and malaria in mice. 29, 30 In humans, increased hepcidin and hypoferremia occur after experimental norovirus, typhoid, and malaria infections, 31-33 and during the initial emergence of viremia in HIV-1-infected blood donors. 34 Although inflammatory hypoferremia can be beneficial in the context of infections with single-cell organisms that must acquire iron from their host, evidence that low serum iron is protective in the context of viral infections is lacking. In fact, in our experiments with influenza virus, imposing hepcidin-induced hypoferremia resulted in an impaired adaptive immune response, viral persistence, and severe pulmonary disease, suggesting that low serum iron may sometimes be an unhelpful response to infection. Recent reports show that hypoferremia is present in coronavirus disease 2019 (COVID-19) patients on admission to the intensive care unit (ICU). 35 Low serum iron correlated with lymphopenia, and extremely low serum iron (~3 mmol/L) identified COVID-19 patients with severe respiratory hypoxemia, likely secondary to pulmonary damage. This hypoferremia is more profound than in previously reported cohorts of non-COVID-19 ICU patients, including those with sepsis, 36, 37 indicating that extreme hypoferremia may be a particular feature of severe COVID-19 disease. IL-6 drives hepcidin expression, and an unbalanced inflammatory response of high IL-6 and relatively low type I and type III IFN associates with severe COVID-19 and poor outcomes. 38,39 IL-6-driven and hepcidin-mediated hypoferremia could impair the antiviral adaptive immune response, contributing to the severity of infection. Tocilizumab, which targets IL-6R, under investigation as a therapeutic for COVID-19, may counteract hypoferremia. Monitoring serum iron in COVID-19 patients may be useful in evaluating disease severity and the effects of treatments.

Previous characterizations of the role of iron in the context of infection describe the attempts of the pathogen to hijack host iron, which the host defends, leading to an evolutionary arms race. 40 We propose that the hypoferremia of infection also represents a trade-off for the host, which attempts to decrease the virulence of invading pathogens by withholding iron, but in so doing simultaneously withholds iron from adaptive immune responses. The outcome of this trade-off will depend on the nature of the causative infection, the magnitude and type of the inflammatory response, and the underlying iron status of the host. Globally, hypoferremia is common in populations in which nutritional iron deficiency is prevalent and in which there is also a burden of infections and inflammation that increase hepcidin, a combination that likely affects hundreds of millions of individuals. 4, 10 As well as influencing responses to infection directly, hypoferremia may have indirect effects on the infectious burden by impairing responses to vaccination. The efficacy and immunogenicity of some vaccines is suboptimal in populations in which iron deficiency is endemic, 41 and in such populations, childhood mortality from vaccinepreventable infections remains unacceptably high. 42 Here, we demonstrate in a piglet model that iron augments responses to vaccination in the context of naturally occurring iron deficiency. Recently, we showed in a retrospective analysis of Kenyan infants that anemia associates with impaired humoral responses to some vaccines and that iron supplementation may enhance the humoral response to a measles vaccine. 43 However, iron can also increase the risk of some infections and adversely influence gut microbiota. 4 Consequently, bespoke trials are needed to determine whether targeted nutritional iron given around the time of vaccinations improves the efficacy of immunizations in populations with iron deficiency, including children and the elderly. Raised hepcidin and hypoferremia in IRIDA patients with mutations in TMPRSS6 may associate with impaired humoral immunity, at least against some pathogens. Persistently high hepcidin and hypoferremia are also features of non-infectious chronic inflammatory disorders such as chronic kidney disease, 9 and inflammation and iron deficiency are observed in cancers. 44 Adaptive immunity in these populations and conditions may be compromised by hypoferremia. Of note, pharmacological or genetic manipulation of hepcidin activity, intended as a therapeutic intervention for iron-related disorders, is relatively well developed. 45 Therefore, hepcidin is already a potentially accessible target and can be investigated as a modality of controlling immune responses in multiple contexts.

While our study found that iron restriction impairs T cell aerobic metabolism as assessed by oxygen consumption and mitochondrial membrane potential, broader hypothesis-free approaches could provide a more holistic appreciation of the mechanism by which limiting iron availability disrupts the function of T cells. Both T and B cell responses are impaired by serum iron deficiency in vivo, but we did not explore how the physiology of isolated B cells is perturbed by iron deficiency or how T cell differentiation is influenced by iron. Furthermore, we have not asked to what extent the impairment of CD8 T cell memory by iron deficiency extends to CD4 and B cell memory and how these observations could affect responses to vaccines and protection against infection.

We found that hepcidin-induced hypoferremia impaired primary and memory responses to immunization, and we uncovered a profound demand of activated T cells for iron mediated at least in part by IRP1/2 and TFRC. High hepcidin can inhibit adaptive immune responses to pathogens, while against a background of low serum iron, supplemental iron can improve immune responses. These results indicate that serum iron, regulated by hepcidin, is an important and potentially targetable control point for immunity.

Detailed methods are provided in the online version of this paper and include the following: T cells with conditional loss of IRP function were derived from animals obtained by crossing mouse lines carrying floxed Irp1 (Aco1) and Irp2 (Ireb2) alleles 49 with a knock-in strain bearing a tamoxifen-inducible CRE recombinase (CreERT2) sequence into the permissive Rosa26 locus. 50 Aco1 flox/flox , Ireb2 flox/flox , Rosa26 +/+ (CRE negative, termed IRP1/2 flox/flox Cre -ve) and Aco1 flox/flox ,Ireb2 flox/flox , Rosa26 +/CreERT2 littermates (CRE positive, termed IRP1/2 flox/flox Cre +ve) were on a homogeneous C57BL/6 background. The breeding and procedures carried out on mice at the DKFZ was done according to institutional guidelines. Mice were genotyped using the Aco1 and Ireb2 primer sequences in the Key Resources Table. Injected substances Minihepcidin: An appropriate mass of mini-hepcidin PR73 29 (da-TH-Dpa-bhPro-RCR-bhPhe-Ahx-Ida(Hexadecylamine)-NH2) was dissolved in 80% ethanol and then mixed with 60mg of Purebright SL220/ Sunbright DSPE-020CN (NOF). The control solution was Purebright SL220 dissolved in ethanol. The ethanol was evaporated off using a vacuum chamber warmed to 50 C. The resultant gel was stored up to 24 hours at 4 C and re-dissolved in an appropriate volume of water to give a mHep concentration of 1mM: 100nMoles of mini-hepcidin in 100 mL of water was injected per mouse per dose.

Ferric ammonium citrate (FAC) (F5879 Sigma Aldrich) was dissolved to 3mg/ml in PBS. 100 mL was injected intraperitoneally into mice. Iron dextran (Sigma, D8517) was adjusted to 20mg/ml in PBS and 100 mL was injected intraperitoneally into mice. 

For experiments involving response of OT-I CD8 or OT-II CD4 T cells, red cell lysed spleen suspensions were obtained and the frequency of OT-I CD8 T cells or OT-II CD4 T cells was evaluated by flow cytometry. The concentration of whole spleen suspension was adjusted to 50,000 OT-I CD8 T cells/ml or 500,000 OT-II CD4 T cells/ml and 100ul of cell suspension in PBS was injected i.v.

For mixed bone marrow chimerism experiments a mix of 60% Tfrc Y20H/Y20H CD45.2 (or WT CD45.2) bone marrow was combined with 40% CD45.1 bone marrow to test the capacity of Tfrc Y20H/Y20H cells to reconstitute and contribute to immune responses relative to wild-type cells. Male CD45.2 recipients at 8-weeks of age received were lethally irradiated with 4.5 Gy for 300 s, followed by a 3-hour rest, and a subsequent 4.5 Gy dose for 300 s. Mice received 2 million total bone marrow cells from the specified mice, after 9-weeks of rest peripheral blood was taken to analyze reconstitution by flow cytometry. To prevent bacterial infection recipient mice received antibiotics in their drinking water (0.16mg/mL Enrofloxacin (Baytril), Bayer Coporation).

Influenza virus (A/X-31 (H3N2) A/Aichi/2/1968) 46 was propagated in MDCK-SIAT1 cells and quantified by hemagglutination assays and TCID 50 as previous described. 47

Mice were anaesthetised with aerosolised isoflurane and infected with 0.08 haemagglutination units (HAU) of influenza virus X-31 intranasally. Virus suspension was pipetted drop wise onto the nares such that the virus is inhaled.

Influenza specific antibody titers in serum of infected mice was measured by in vitro microneutralisation assays of infection of MDCK-SIAT1 cells with a H3N2 (X31) GFP expressing pseudotyped reporter virus (S-FLU) as described 47 with minor modifications. In brief, collected mouse sera was heat inactivated at 56C for 30min. Dilutions of sera (starting dilution 1:40) was incubated with H3N2 (X31) S-FLU for 2 hours at 37C before addition of 3e4 of indicator MDCK-SIAT1 cells. Plates were incubated overnight at 37C. Plates were then washed and fixed in 10% formalin. GFP expression was measured on a Clariostar plate reader and the dilution of sera that resulted in 50% reduction of infection of the virus (determined via 50% reduction in GFP signal) was reported as the neutralising titer (EC 50 ). Ethical Review Body (AWERB) and were performed under a UK Home Office License.

To assess the impact of iron deficiency on responses to vaccination, 18 large white F1 hybrid piglets from 6 litters were distributed evenly between 2 sex-matched treatment groups at 1 day old. Treatments were: group 1: Non-iron supplemented control, fed sow milk replacer (SMR) similar to bovine-based infant formula milk; group 2: fed iron supplemented (150mg/kg BW) SMR, half this group also received an intramuscular (IM) iron injection (200mg Fe) at 1 day old ( Figure S6 ). Prior to their arrival at CEDAR, the piglets did not receive vaccinations, antibiotics or standard husbandry IM iron injections. Initially piglets were housed in 2 groups (oral iron and no oral iron supplementation) in order to learn to drink from bowls and at 2 days old were individually housed. Throughout the trial piglets were housed at 30 C on sawdust and straw and provided with heat lamps under a 12h light and dark cycle and had free access to fresh drinking water. Piglets were initially fed 10% SMR concentration (either iron supplemented or non-supplemented) every 4 hours (5 feeds/day) and this was increased to 15% and finally to 20% (4 feeds/day, standard concentration) by day 4 in order to reduce the risk of scouring. Following twice-a-week weight measurements, the amount of SRM and ferrous sulfate (oral iron supplementation) was increased accordingly to achieve 150mg/kg body weight throughout the trial. All piglets received an IM vaccination against Mycoplasma hyopneumoniae (2ml, Suwaxyn MH-One, Zoetis Ltd, Leatherhead, UK) at 2 weeks old and blood samples were collected via venepuncture using non-EDTA vacutainers at 2 weeks (pre-vaccination), 3 and 4 weeks old (post-vaccination). Blood was immediately refrigerated for 3-4 hours before being centrifuged to obtain serum, which was stored at À80 C. At 28 days, piglets were killed by overdose of pentobarbital sodium BP 20% (Dolethal, Vetoquinol Ltd, Northamptonshire, UK).

Collection, genotyping, and hematological phenotyping of IRIDA and control patients has been described previously. 51

Cell culture All cells were cultured at 37 C, 20% O 2 and 5% CO 2 . Media. Complete R10. RPMI with 10% FCS (sigma), glutamine (2mM), penicillin (100U/ml), streptomycin (0.1mg/ml) and Beta-mercaptoethanol (55mM). Iron modified culture medium. Pannexin NTS serum substitute (P04-95080; Pan Biotech) lacking iron was ordered. Iron free Pannexin NTS serum substitute was added at 10% v/v to RPMI alongside glutamine (2mM), penicillin (100U/ml), streptomycin (0.1mg/ml) and Beta-mercaptoethanol (55mM) to make iron free complete medium. To modify the iron content of the iron free complete medium, holotransferrin (T0665 Sigma Aldrich) was added at the specified concentration. Apotransferrin (T1147 Sigma Aldrich) was also added to iron free complete medium to maintain the total transferrin concentration of the medium at 1.2mg/ml. CD8 T cells. Single cell suspensions were made from cervical, inguinal, axillary and brachial lymph nodes by mechanical dissociation through a 40 mm cell strainer. When proliferation was analyzed lymph node suspensions were resuspended in 500 mL of PBS with 5mM Invitrogen Cell Trace Violet (C34557) and stained at 37 C for 8 minutes before quenching with 12ml of complete medium, washing and proceeding to T cell isolation. CD8 T cells were isolated from the lymph nodes of WT C57BL/6, Tfrc Y20H/Y20H , OT-I CD45. Flat bottom tissue culture treated plates were coated with 5 mg/ml of anti-mouse CD3 (145-2C11) for 2 hours at 37 C and then washed with PBS. CD8 T cells were plated in complete medium with a final concentration of 100U/ml mouse IL-2 and 1 mg/ml anti-mouse CD28 (37.51). Cultures involving Tfrc Y20H/Y20H , WT C57BL/6 cells or IRP1/2 flox/flox Cre -/+ ve were carried out in complete R10 medium. Cultures examining the effect of reduced iron concentration on WT T cells from C57BL6/ or OT-1 CD45.1 mice were performed in iron free complete medium. CD8 T cells were plated at a final concentration of 500,000/ml for analysis at 72hrs post activation for proliferation analysis or 700,000/ml for analysis at 24hrs post activation for activation analysis.

For culture of IRP1/2 flox/flox Cre -/+ ve cells were treated with either 4-hydroxytamoxifen (4-OHT) (H6278, Sigma/Merck) at 100nM or a comparable volume of pure ethanol concurrent with the activation mixture of soluble anti-CD28, IL-2 and plate-bound anti-CD3. When cell proliferation was to be analyzed, after 24hrs of culture cells were harvested, spun down and resuspended in fresh medium with 100U/ ml mouse IL-2 and 1 mg/ml anti-mouse CD28 to remove 4-OHT or EtOH and replated in wells coated with anti-mouse CD3. Cells were cultured for an additional 48hrs and proliferation was evaluated by flow cytometry.

For iron rescue experiments iron sulfate (FeSO 4 ) (F8633, Sigma Aldrich) or ferric ammonium citrate (FAC) (F5879, Sigma Aldrich) was added at the indicated concentration from the start of culture and replenished in the case of the IRP1/2 flox/flox Cre -/+ ve experiments after 24hrs when 4-OHT/EtOH was removed.

BMDCs were cultured as described 52 with minor modifications. In brief, red cell lysed bone marrow cells from C57BL/6 mice were resuspended at 1 million cells/ ml in complete R10 medium with 100ng/ml FLT3L (550702, Biolegend) and cultured for 7 days before use. Figure 1A ) and effect of minihepcidin on tetramer positive CD8s (Supplementary Methods Figure 1B) . Figure 4A ) and effect of minihepcidin on plasma (Supplementary Methods Figure 4B ). CD8+ CD45.1+ OT-I CD8s (Supplementary Methods Figure 5A ) and effect of minihepcidin on OT-I effector cells (Supplementary Methods Figure 5B ). Gating of OT-I IFN-gamma, TNF-alpha or IL-2 producing CD8 T cells by ICS (Supplementary Methods Figure 6A ) and effect of minihepcidin on cytokine producing CD8 T cells (Supplementary Methods Figure 6B ).

Gene expression analysis by quantitative real time PCR (qRT-PCR) RNA was extracted from liver explants or lung lobes harvested into RNA later (AM7020 Thermofisher Scientific) and snap frozen cell pellets with the RNeasy plus kit (QIAGEN, 74136) and reverse transcribed to cDNA (Life Technologies, 4387406) for quantitative PCR on the Applied Biosystems 6500 Fast Real-Time PCR system machine using TaqMan assays listed in the Key Resources Table. according to the manufacturer's protocols. Gene expression is presented as 2^([CT of endogenous control gene] -[CT of gene of interest]). Hprt was used an endogenous control gene for liver and lung qRT-PCR. B2m was used as a control gene for CD8 T cell cultures as the CT does not change during T cell activation.

Tissues were dried for 3 hours at 100 C, and the dry mass of tissue piece was measured. Tissue pieces were digested in 10% trichloroacetic acid/ 30% hydrochloric acid for 20 hours at 65 C. Non-haem iron content was determined by reaction of the acid digested tissue with chromogen reagent containing 0.1% (w/v) bathophenanthrolinedisulphonic acid (Sigma, 146617) and 0.8% thioglycolyic acid (Sigma, 88652) measuring absorption at 535nm and comparing to a standard curve of ferric ammonium citrate as described. 54

For serum analysis of murine samples up to 400ml of blood obtained by cardiac puncture was placed in a BD microtainer SST tube (Beckton Dickinson). Serum was obtained by spinning the clotted blood sample was spun at 8,000 g for 5 minutes and stored at À80 C. Serum iron was quantified using the Abbott Architect c16000 automated analyzer (Abbott Laboratories) and the MULTIGENT Iron Kit at Oxford John Radcliffe Hospital, UK.

Pig serum iron was measured using an automated assay on an Abbott Architect c16000 automated analyzer (Abbott Laboratories) in the Department of Clinical Biochemistry, OUHNHS. Serum samples were tested for M. hyopneumoniae antibodies using a commercial monoclonal blocking ELISA (M. hyopneumoniae detection kit, Thermo Scientific Oxoid, UK, K004311) according to manufacturer's instructions at Biobest Laboratories Ltd, Edinburgh; sample optical density (OD) results were corrected using the mean OD of buffer control wells. Serum titers of neutralising antibodies (agnostic of isotype) were calculated as a percentage blocking of signal derived from binding of the defined anti-M. hyopneumoniae HRP conjugated antibody included in the assay. Results were reported as improvement in % block on day 28 (14 days post immunisation) relative to day 14 (day of immunisation) to detect improvement in antibody responses above inherited maternal antibody. Improvement in % block = (% block on day 28) -(% block on day 14).

Antibody titers against OVA protein from immunized mice were determined by ELISA. In, brief, plates were coated with OVA protein (InvivoGen Endofit,

Med 2, 164-179.e1-e12, February 12, 2021 e10 50 ml/well at 10 mg/ml) over night. Dilutions of test sera (in triplicate) were added to the plate. Plates were washed 6 times with PBS-T (PBS, 0.05% Tween). To detect OVA binding IgG, the goat anti-mouse secondary Ab binding an alkaline-phosphatase-conjugated goat anti-mouse IgG (Sigma Aldrich A-3562), followed by further washing. OD 405 after addition of pNPP substrate was quantified using an ELx800 plate reader (Bio-Tek). The dilution at which the OD was first below background + 3 SD was recorded in AU as the endpoint titer.

Human sera antibody measurements in IRIDA patients Antibody concentrations (IgG) against Measles, Mumps, Rubella, Varicella, Ptx, FHA, Prn, Dtxd, Ttx, Hib, and Steptococcus pneumoniae seroptypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in sera from IRIDA patients with mutant TMPRSS6 alleles and non-iron deficient wild-type TMPRSS6 controls were measured at National Institute for Public Health and the Environment, Bilthoven, Netherlands. In no case was mean antibody concentration significantly higher in TMPRSS6 patients.

To evaluate airway inflammation, lung samples were fixed with 4% paraformaldehyde in phosphate buffer and embedded in paraffin at the HEMS core facility at i3S, Portugal. Following deparaffinization with xylene and hydration by a passage through a grade of alcohols, 3mm-thick sections were stained with hematoxylineosin. Histopathology scores for pulmonary inflammation were assigned using modified criteria 55 as follows: 0, normal, no inflammation; 1, minimal, rare foci of inflammation; 2, mild, inflammatory cell infiltrate of the perivascular/peribronchiolar compartment with none or scarce alveolar extension; 3, moderate, inflammatory cell infiltrate of the perivascular/peribronchiolar space with modest extension into the alveolar parenchyma; and 4, severe, inflammatory cell infiltrate of the perivascular/peribronchiolar space with a greater magnitude of inflammatory foci found in the alveolar parenchyma. Neutrophilic infiltration was classified as 0, no evidence of polymorphonuclear leukocytes (PMN); 1, presence of dispersed PMN; 2, frequent PMN with focal aggregation; 3, frequent PMN with multifocal aggregation. Neutrophil infiltration was further evaluated with the chloracetate esterase (Leder) stain, performed at the Anatomic Pathology Service at Centro Hospitalar de Sã o Joã o, Portugal. Orcein staining (performed at IPATIMUP Diagnostics, Portugal) was used to evaluate the elastic fibers of the alveolar septa and assess the degree of alteration of the alveolar lung structure associated to the presence of the inflammatory infiltrate. Sections were scored by two investigators, including a trained pathologist in a blinded manner without prior knowledge of the treatment groups. The mean score was calculated and compared between treatment groups. Spleen sections were processed similarly, but stained with Perls' Prussian blue reaction for ferric iron using standard procedures.

ATP production rate by Seahorse metabolic flux analysis ATP production rate and the relative contribution of mitochondrial and glycolytic metabolism to this was calculated as per manufacturer's protocol using the Agilent Seahorse XF real-time ATP rate assay kit (103592-100) and an Aligent XF96 instrument. In brief CD8 T cells were harvested after 48 hours of activation in media with the specified transferrin concentration, washed, resuspended in Seahorse Assay Media (unbuffered RPMI pH 7.40 with 1mM pyruvate, 2mM L-glutamine and 10mM Glucose) and 150,000 viable cells/well were aliquoted into a Poly-D-lysine coated XF96 microplate. Oxygen consumption rates (OCR) and extracellular ll OPEN ACCESS e11 Med 2, 164-179.e1-e12, February 12, 2021 acidification rates (ECAR) were measured upon sequential addition of 1.5 mM Oligomycin and 0.5 mM Rotenone/Antimycin A.

ATP quantification by luminescence ATP production was measured using Cell Titer-Glo (Promega G7570) according to manufacturer's instructions. In brief CD8 T cells were cultured as described in 'cell culture' for 24 hr (and therefore analyzed to prior to the initiation of cell division), spun down and resuspended in 50 mL of medium (iron free for iron deficiency cultures, normal RPMI with 10% FCS for Tfrc Y20H/Y20H cultures), transferred to a white walled opaque 96-well plate appropriate for luminescence measurements and 50 mL of Cell Titer-Glo was added. Wells were mixed and luminescence, proportional to ATP content, was measured on a Promega GloMax Luminometer.

Standard randomization procedures were used for in vivo experiments mice of the same age and sex (experimental and control mice were chosen at random from among littermates). The investigators were not blinded to allocation during experiments and assessments. The required number of mice for each experiment was determined from availability of bred animals, power calculations, prior experience of performing experiments with the same strains of mice and data from pilot experiments. Statistical analyses were performed using Prism version 6 (GraphPad Software). Details of specific statistical tests are given in figure legends.

For antibody concentrations of TMPRSS6 IRIDA patients, we conducted statistical analyses with SPSS (IBM SPSS statistics, Version 22). Data were checked for normality by Smirnov-Kolmogorov tests and by visual inspection of histogram plots. Non-normally distributed data were logarithmically transformed for statistical analyses. We defined immunological response as protective when participants had anti-diphtheria serum IgG concentrations R 0$1IU/ml, 56 anti-tetanus IgG > 0.5IU/ml, 57 anti-Hib IgG > 1.0mg/ml, 57 anti-PCV IgG R 0$35 mg/ml 58 and anti-measles IgG R 0$12IU/ml. 59 There is no protective serum concentration established for antipertussis IgG. 57 For between-group effects, independent sample t tests or independent sample non-parametric tests were used. We performed analysis of covariance (ANCOVA) to assess the effect of group (IRIDA versus control) on serum IgG concentrations. Group was defined as fixed effect and we sequentially added known predictors of vaccine response: gender, age, Hb, TSAT as covariates to the models. We performed Pearson Chi-Square test and Fisher's Exact test to compare seroconversion between the IRIDA and control groups.

Supplementary 

A B Figure S4 . Iron uptake via the transferrin receptor is required for optimal activation prior to division, relating to figure 4. A Experimental scheme for investigation of effect Tfrc Y20H/Y20H mutation of CD8 T cell activation in vitro. In all cases the improvement in the parameter in question in iron-supplemented cells vs non-iron-supplemented cells is reported. B % of CD69+ cells was measured by flow cytometry. Mean ± sd. Two-way ANOVA blocking for effect of experiment replicate and genotype, reported p value is genotype effect. C ATP production was measured using Cell Titre Glo kit. The MFIs of mitotracker deep red (MTDR) and mitotracker green (MTG) were measured by flow cytometric analysis and the ratio of MTDR to MTG was calculated. FSC MFI and the % of pS6 expressing cells was measured by flow cytometry. Presented as a combination of two or three independent experiments (indicated by different data point shapes). Mean ± sd. Two-way ANOVA blocking for effect of experiment replicate and genotype, reported p value is genotype effect. D WT and Tfrc Y20H/Y20H activated for 72hours in the presence or absence of FeSO4, proliferation was resolved by flow cytometric analysis of cell trace violet dilution and the % of cells which had diluted CTV more than once reported as 'divided'. Left: Representative cell trace violet profiles and effect of genotype and iron on % of CD8 T cells divided. Mean ± range. Right: Two-way ANOVA, multiple comparisons for treatment at each iron level. Figure S6 . Piglet iron supplementation study, and IRIDA patient phenotype and response to Streptococcus pneumoniae vaccination, relating to figure 6. A Experimental design for investigation of effect of iron supplementation of piglet physiology and vaccine responses. B RBC and platelet counts were measured at 28 days of age in piglets. Mean +/-range. C Anti-M. hyopneumoniae antibody presented as % block on day 14 (baseline, day of immunisation), left. Mean ± sd Students two tailed T-test, unpaired. Change in % block with time: % block on day 14 and day 28, with lines connecting paired data for each piglet, right. Two-way ANOVA reporting significant interaction of effect of diet and time. D Transferrin saturation, serum iron, ferritin, hepcidin, Hb, haematological parameters and CRP of IRIDA patients expressing mutant TMPRSS6 and non-anaemic wild-type TMPRSS6 controls. Mean ± sd, geometric mean ± geometric sd for logged CRP data. Students two tailed T-test, unpaired. E Ab concentrations against all Streptococcus pneumoniae serotypes analysed individually, and in combination. Mean ± SD. Students two tailed T-test, unpaired. Rightmost panel: Analysis of the frequency of measurements for both genotypes with Ab concentrations against each Streptococcus pneumoniae serotype that exceeds the protective threshold of 0.35ug/mL. Fisher exact test. 

Metabolic and epigenetic coordination of T cell and macrophage Immunity

The human iron-proteome

A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency

Reducing anaemia in low income countries: control of infection is essential

A Red Carpet for Iron Metabolism

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

Nrf2 controls iron homeostasis in haemochromatosis and thalassaemia via Bmp6 and hepcidin

Hepcidin and the iron-infection axis

Anemia of Inflammation

Rapid growth is a dominant predictor of hepcidin suppression and declining ferritin in Gambian infants

Respiratory infections drive hepcidin-mediated blockade of iron absorption leading to iron deficiency anemia in African children

Iron deficiency and the immune response

Iron and its relation to immunity and infectious disease

Iron Drives T Helper Cell Pathogenicity by Promoting RNA-Binding Protein PCBP1-Mediated Proinflammatory Cytokine Production

Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses

Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload